Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 95

Results For "regulatory"

1220 News Found

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
News | February 19, 2022

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'

Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).


Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation
News | February 19, 2022

Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study


Indian pharma industry needs a winning partnership
News | February 19, 2022

Indian pharma industry needs a winning partnership

The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines


UAE to recognise Indian pharma products within three months
News | February 19, 2022

UAE to recognise Indian pharma products within three months

The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.


Modis and ValGenesis partner to bring Best-in-Class validation processes to Italian pharma
Digitisation | February 18, 2022

Modis and ValGenesis partner to bring Best-in-Class validation processes to Italian pharma

The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance


Bayer raises peak sales for Nubeqa to exceed €3 billion
News | February 18, 2022

Bayer raises peak sales for Nubeqa to exceed €3 billion

Darolutamide is developed jointly by Bayer and Orion Corporation


Ligand posts strong 2021 performance
News | February 18, 2022

Ligand posts strong 2021 performance

Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.


Moderna’s Covid-19 vaccine approved in Australia for children (6-11 years)
News | February 17, 2022

Moderna’s Covid-19 vaccine approved in Australia for children (6-11 years)

Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia


Pebble engages MD Anderson to evaluate multi-cannabinoid formulations in ovarian cancer
Biotech | February 17, 2022

Pebble engages MD Anderson to evaluate multi-cannabinoid formulations in ovarian cancer

Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care


PerkinElmer’s SIRION Biotech and CRG to develop diabetes gene therapy
Biotech | February 17, 2022

PerkinElmer’s SIRION Biotech and CRG to develop diabetes gene therapy

Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy